Journal
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
Volume 17, Issue -, Pages 1-12Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.nano.2018.12.013
Keywords
Bismuth (bi) chalcogenides; Doxorubicin; Chlorin e6; Controlled drug release; Cancer theranostics
Funding
- Technology Innovation and Application Demonstration Grant of Chongqing [cstc2018jscx-msybX0078]
- Fundamental Research Funds for Central Universities [XDJK2017C001, XDJK2016A010]
- National Natural Science Foundation of China [51703186, 31671037]
Ask authors/readers for more resources
Taking advantage of the mesoporous structure of bismuth sulfide nanostars (Bi(2)S(3 )NSs), a chemotherapeutic drug of doxorubicin (DOX) and a photosensitizer of chlorin e6 (Ce6) were concurrently loaded in the PEGylated Bi(2)S(3 )NSs to formulate a multifunctional nanocomplex (BPDC NSs) for tumor theranostics. BPDC NSs have excellent photothermal conversion efficiency and a capacity of yielding reactive oxygen species (ROS) upon laser irradiation, and can realize on-demand drug release by either pH-activation or thermal induction. Accumulation of the nanodnig could be monitored in real-time by infrared thermal imaging, fluorescence imaging and computed tomography (CT). More importantly. the combination effects of photothermal therapy (PTT), photodynamic therapy (PDT) and chemotherapy were demonstrated to dramatically suppress solid tumors without recurrence in vivo. Featuring low systemic toxicity and high biocompatibility, this nanoplatform could be a promising derivative of Bi2S3 NSs for imaging-guided theranostics of cancer. (C) 2019 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available